# OnCo record tk216 (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/tk216/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "tk216" ;
  schema:name "TK216"@en ;
  schema:alternateName "TK-216"@en ;
  schema:description "TK216 was an attempt to hit the fusion protein that causes Ewing sarcoma directly, something long thought impossible for a transcription factor. In early trials with vincristine it produced a few responses but not enough to carry the drug forward."@en ;
  schema:url <https://onco.cc/drugs/tk216/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  onco:status "phase-2" ;
  onco:tag "subtype-drugs-wave" ;
  onco:modality "Small-molecule EWS-FLI1 inhibitor" ;
  onco:related <https://onco.cc/drugs/vincristine/>, <https://onco.cc/drugs/lurbinectedin/> ;
  onco:cancers <https://onco.cc/cancers/ewing-sarcoma/> ;
  onco:targets <https://onco.cc/targets/ewsr1-fli1/> ;
  onco:companies <https://onco.cc/companies/oncternal-therapeutics/> .